|
|
| Line 1: |
Line 1: |
| ==List of indications==
| | #REDIRECT [[Clopidogrel#Adult Indications and Dosage]] |
| <br>
| |
| Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows:
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Clopidogrel indications#Recent MI, Recent Stroke or Established Peripheral Arterial Disease|Recent MI, Recent Stroke or Established Peripheral Arterial Disease]]</font>
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Clopidogrel indications#Acute Coronary Syndrome|Acute Coronary Syndrome]]</font>
| |
| <br>
| |
| <br>
| |
| <br>
| |
| <br>
| |
| -------
| |
| <br>
| |
| | |
| ===Recent MI, Recent Stroke or Established Peripheral Arterial Disease===
| |
| | |
| For patients with a history of recent [[myocardial infarction]] (MI), recent [[stroke], or established [[peripheral arterial disease]], [[clopidogrel]] has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
| |
| | |
| ''[[Clopidogrel indications#List of indications|Return to top]]''
| |
| <br>
| |
| | |
| ===Acute Coronary Syndrome===
| |
| | |
| For patients with [[acute coronary syndrome]] ([[unstable angina]] / non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with [[percutaneous coronary intervention]] (with or without stent) or [[CABG]], [[clopidogrel]] has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia
| |
| | |
| ''[[Clopidogrel indications#List of indications|Return to top]]''
| |
| <br>
| |
| | |
| | |
| {{FDA}}
| |
| | |
| | |
| | |
| | |
| [[Category:Drugs]]
| |